United States: The Federal Trade Commission rules that two pharmaceutical laboratories concluded an unlawful pay-for-delay agreement (Endo / Impax)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. No loosening of deferral of entry agreements appears to be the direction given to FTC officers. In its Opinion written by Noah Joshua Phillips, the U.S. Competition Authority